Recognizing the Early Warning Signs of PML in Tysabri Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Occupational and Legal Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like weakness, vision changes, or confusion, it is important to understand the potential link to progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance research have established that PML is a rare but serious brain infection associated with certain immunosuppressive therapies. This page provides a clear overview of the symptoms, risk factors, and what to do if warning signs appear.

Medical Background and Clinical Presentation of Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations for filing a claim—is essential. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition is caused by the JC virus, which remains latent in many people but can reactivate when immune surveillance is impaired. In Tysabri-treated patients, PML presents with progressive neurological deficits such as confusion, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because the disease can advance rapidly.

Pharmacology, Risk Factors, and Mechanistic Pathways

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration into the brain and gut. This mechanism reduces inflammation in multiple sclerosis and Crohn’s disease but also impairs immune surveillance against JC virus in the central nervous system. The prescribing information identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic link between Tysabri and PML involves reduced immune cell trafficking to the brain. By blocking VLA-4 integrins, Tysabri prevents T cells and other immune cells from crossing the blood-brain barrier. This diminishes the ability to control JC virus replication in oligodendrocytes, leading to lytic infection and demyelination. The risk is highest in patients with pre-existing anti-JCV antibodies, as these indicate prior exposure to the virus. Prolonged treatment duration further increases risk because sustained immune suppression allows viral reactivation over time.

Adequacy of Warnings and the TOUCH Prescribing Program

Tysabri carries a boxed warning stating that it increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, prescribers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions about adequacy may arise if patients were not fully informed of the risk or if monitoring protocols were not followed.

Settlement-Related Considerations and Florida Statute of Limitations

For affected patients in Florida, settlement considerations involve the timeline between Tysabri exposure and documented harm. PML typically develops after months to years of treatment, with risk increasing beyond two years. The statute of limitations for filing a product liability or personal injury claim in Florida is generally two years from the date the injury was discovered or should have been discovered. This means that patients diagnosed with PML must act promptly to preserve their legal rights. Settlement negotiations may consider the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings or failure to monitor. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Florida?

In Florida, the statute of limitations for product liability or personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For Tysabri-associated PML, this means patients diagnosed with PML must act promptly to preserve their legal rights.

What are the key risk factors for developing PML while on Tysabri?

The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.